IMR Press / EJGO / Volume 19 / Issue 2 / pii/1998134

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Thyroid function in postmenopausal women with breast cancer on tamoxifen

Show Less
1 Department of Medical Physics, Medical School, University of Athens, Greece
2 2nd Department of Propedeutic Surgery, Medical School, University of Athens, Greece
3 Department of Medicine, RPMS, Hammersmith Hospital, London, United Kingdom
Eur. J. Gynaecol. Oncol. 1998, 19(2), 150–154;
Published: 10 April 1998

In 42 postmenopausal women with breast cancer, aged 48-85 years (mean age 62.4 years) serum thyroid hormone concentrations were measured before and after 6 months of tamoxifen therapy (20 mg daily). In particular triiodothyronine (T3), thyroxine (T4), free triiodothyronine (FT3), free thyroxine (FT4), thyroxine-binding globulin (TBG) and thyroid-stimulating hormone (TSH) con­centrations before and 30 minutes after thyrotrophin-releasing hormone (TRH) administration (200 µg I. V.) were measured before and 6 months after tamoxifen therapy. T, and T4 concentrations increased significantly (p < 0.001 and p < 0.05, respectively) whereas FT1 and FT4 remained unchanged (p > 0.05), TBG increased significantly (p < 0.001) and basal TSH concentrations as well as TSH response to TRH injection increa­sed significantly (p < 0.05) after tamoxifen therapy. It is concluded that tamoxifen administration changes thyroid hormone concentrations. However free thyroid hormone levels remain unchanged and the patients remain euthyroid after long-term tamoxifen therapy.

Breast cancer
Thyroid function
Thyroid hormones
Back to top